HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab

HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab Case Report HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab 1,2 1,3 4,5 2,6 Elaine Chang, Gustavo Rivero, Niraj R. Patel, Elizabeth Y. Chiao, 8,9 1 7 1,3 Syeling Lai, Kelash Bajaj, John E. Mbue, Sarvari V. Yellapragada Clinical Practice Points We present a case of a veteran with well-controlled unique biology, particularly the near-universal asso- human immunodeficiency virus (HIV) infection and ciation with Epstein-Barr virus, regardless of histology, primary refractory classical Hodgkin lymphoma (HL) suggests that immunotherapy may have an important who, after multiple prior lines of therapy, received role in the management of this disease. nivolumab with a complete response. He also devel-  Most clinical trials highlighting checkpoint inhibitors oped autoimmune diabetes mellitus after 6 months of have excluded HIV-infected patients. More prospec- nivolumab. tive data is clearly needed to delineate the risks and HIV-associated HL is currently treated under the same benefits of immunotherapy in this population with algorithm as HL in the general population, but its increased autoimmunity at baseline. Clinical Lymphoma, Myeloma & Leukemia, Vol. 18, No. 2, e143-6 ª 2017 Elsevier Inc. All rights reserved. Keywords: Anti-PD-1, Autoimmune diabetes, Human immunodeficiency virus, Immune checkpoint inhibitor, Immune-related adverse event http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Lymphoma Myeloma and Leukemia Elsevier

HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab

Loading next page...
 
/lp/elsevier/hiv-related-refractory-hodgkin-lymphoma-a-case-report-of-complete-mHGcmnopTD
Publisher
Elsevier
Copyright
Copyright © 2017 Elsevier Inc.
ISSN
2152-2650
eISSN
2152-2669
D.O.I.
10.1016/j.clml.2017.12.008
Publisher site
See Article on Publisher Site

Abstract

Case Report HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab 1,2 1,3 4,5 2,6 Elaine Chang, Gustavo Rivero, Niraj R. Patel, Elizabeth Y. Chiao, 8,9 1 7 1,3 Syeling Lai, Kelash Bajaj, John E. Mbue, Sarvari V. Yellapragada Clinical Practice Points We present a case of a veteran with well-controlled unique biology, particularly the near-universal asso- human immunodeficiency virus (HIV) infection and ciation with Epstein-Barr virus, regardless of histology, primary refractory classical Hodgkin lymphoma (HL) suggests that immunotherapy may have an important who, after multiple prior lines of therapy, received role in the management of this disease. nivolumab with a complete response. He also devel-  Most clinical trials highlighting checkpoint inhibitors oped autoimmune diabetes mellitus after 6 months of have excluded HIV-infected patients. More prospec- nivolumab. tive data is clearly needed to delineate the risks and HIV-associated HL is currently treated under the same benefits of immunotherapy in this population with algorithm as HL in the general population, but its increased autoimmunity at baseline. Clinical Lymphoma, Myeloma & Leukemia, Vol. 18, No. 2, e143-6 ª 2017 Elsevier Inc. All rights reserved. Keywords: Anti-PD-1, Autoimmune diabetes, Human immunodeficiency virus, Immune checkpoint inhibitor, Immune-related adverse event

Journal

Clinical Lymphoma Myeloma and LeukemiaElsevier

Published: Feb 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off